Finance

Lists
Why is MRK up 3,12%?
Dive Deeper
MRK:ETR
Merck KGaA
141,90 €
+3,12%
(+4,30) 1D
14-окт., 17:37:35 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for MRK...
Open
138,00 €
High
141,95 €
Low
137,40 €
Mkt. cap
18,29 млд
Avg. vol.
288,82 миң
Volume
276,60 миң
Dividend
1,55%
Quarterly dividend
0,55 €
Ex-dividend date
2026-ж., 27-апр.
P/E ratio
26,02
52-wk high
148,80 €
52-wk low
100,70 €
EPS
5,45 €
Shares outstanding
129,24 млн
No. of employees
62 миң
Open
138,00 €
High
141,95 €
Low
137,40 €
Mkt. cap
18,29 млд
Avg. vol.
288,82 миң
Volume
276,60 миң
Dividend
1,55%
Quarterly dividend
0,55 €
Ex-dividend date
2026-ж., 27-апр.
P/E ratio
26,02
52-wk high
148,80 €
52-wk low
100,70 €
EPS
5,45 €
Shares outstanding
129,24 млн
No. of employees
62 миң
News stories
From web sources and news partners
Profile
The Merck Group, branded and commonly known as Merck, is a German multinational science and technology company headquartered in Darmstadt, with about 60,000 employees and a presence in 66 countries. The group includes around 250 companies; the main company is Merck KGaA in Germany. The company is divided into three business lines: Healthcare, Life Sciences and Electronics. Merck was founded in 1668 and is the world's oldest operating chemical and pharmaceutical company, as well as one of the largest pharmaceutical companies globally. Merck operates in Europe, Africa, Asia, Oceania and the Americas. It has major research and development centres in Darmstadt, Boston, Shizuoka and Beijing, as well as other Research and Development units in Taiwan, France, Israel, South Korea, India, and the UK. Merck pioneered the commercial manufacture of morphine in the 19th century and for a time held a virtual monopoly on cocaine. Merck was privately owned until going public on the Frankfurt Stock Exchange in 1995 and is listed on the DAX index of Germany's top companies. The Merck family still controls a majority of 70.3% of the company's shares. Wikipedia
About Merck KGaA
CEO-
Employees62,1 миң
Founded1668
Headquarters-
SectorPharmaceutical industry
Last report
2026-ж., 6-авг.
Fiscal period
Q2 2026
2,16 € / 2,05 €
+5,32%beat
Revenue / Est. (EUR)
5,43 млд / 5,30 млд
+2,44%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
5,32 млд
5,25 млд
5,13 млд
5,43 млд
Cost of goods sold
2,10 млд
2,20 млд
2,07 млд
2,27 млд
Cost of revenue
2,10 млд
2,20 млд
2,07 млд
2,27 млд
Research and development expenses
660,00 млн
634,00 млн
657,70 млн
684,00 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,46 млд
1,54 млд
1,52 млд
1,56 млд
Operating expense
1,99 млд
2,12 млд
2,13 млд
2,41 млд
Total operating expenses
4,10 млд
4,32 млд
4,20 млд
4,68 млд
Operating income
1,22 млд
926,00 млн
935,40 млн
753,00 млн
Other non operating income
1,00 млн
4,00 млн
-100,00 миң
-1,00 млн
EBT including unusual items
1,12 млд
401,00 млн
868,70 млн
640,00 млн
EBT excluding unusual items
1,12 млд
1,10 млд
867,50 млн
640,00 млн
Income tax expense
225,00 млн
77,00 млн
200,00 млн
146,00 млн
Effective tax rate
20,04%
19,20%
23,02%
22,81%
Other operating expenses
-128,00 млн
-50,00 млн
-45,40 млн
164,00 млн
Net income
902,00 млн
319,00 млн
659,40 млн
490,00 млн
Net profit margin
16,96%
6,08%
12,84%
9,02%
Earnings per share
-
-
-
2,16
Interest and investment income
27,00 млн
21,00 млн
21,20 млн
25,00 млн
Interest expense
-126,00 млн
-43,00 млн
-80,60 млн
-137,00 млн
Net interest expenses
-99,00 млн
-22,00 млн
-59,40 млн
-112,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
1,68 млд
1,31 млд
1,42 млд
1,25 млд
Gain or loss from assets sale
-174,00 млн
6,00 млн
-41,90 млн
1,00 млн
AI content may include mistakes. Learn more
Google колдонмолору